Lobbying Filing Details

Total Spending

$370,000

Activities

4

Lobbyists

2

Gov't Entities

8

Filing Information
Filing UUID:
066f8120-f225-4abc-afce-d7d9a1cff811
Type:
Q4 - 4th Quarter - Report
Period:
2022 - 4th Quarter (Oct 1 - Dec 31)
Date Posted:
January 18, 2023 at 4:01 PM
Income:
$0
Expenses:
$370,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Samantha Ventimiglia
Registrant
VERTEX PHARMACEUTICALS INCORPORATED

Global biotechnology company

Boston, Massachusetts
Client
VERTEX PHARMACEUTICALS INCORPORATED
Massachusetts, United States of America
Lobbying Activities (4)
Activity 1
Budget/Appropriations

Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.

Lobbyists (2)
  • SAMANTHA VENTIMIGLIA
  • MATTHEW O SCHUMAKER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Health Issues

Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.

Lobbyists (2)
  • SAMANTHA VENTIMIGLIA
  • MATTHEW O SCHUMAKER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Medical/Disease Research/Clinical Labs

Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."

Lobbyists (2)
  • SAMANTHA VENTIMIGLIA
  • MATTHEW O SCHUMAKER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 4
Taxation/Internal Revenue Code

Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).

Lobbyists (2)
  • SAMANTHA VENTIMIGLIA
  • MATTHEW O SCHUMAKER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.